VENUS Study | Publications

Kawazoe Y*, Katsuta T, Tanaka T, Nakamura Y, Sato S, Maeda M, Oda F, Fukuda H.

Prevalence of HPV Vaccine–Associated Symptoms in Unvaccinated Japanese Adolescents: A Descriptive Study from the VENUS Study Database.

Vaccine 2026; in press.

Sazawa M, Ishiguro C, Mimura W, Maeda M, Murata F, Fukuda H.

Impact of the resumption of proactive recommendation of HPV vaccination on HPV vaccination rates in Japan: An interrupted time series analysis based on the VENUS Study.

BMJ Public Health 2026; in press.

Ishiguro C*, Mimura W, Oda F, Maeda M, Fukuda H.

Population-Based Cohort Study Assessing the Effectiveness of Maternal BNT162b2/mRNA-1273 Vaccination Against Infant Coronavirus Disease 2019 Outcomes During Omicron Predominance: The VENUS Study .

Human Vaccines & Immunotherapeutics 2025; 21(1): 2585595.

Maeda M, Murata F, Fukuda H.

Effects of the introduction of a routine rotavirus vaccination program on vaccination coverage and factors in a Japanese municipality: The VENUS Study.

BMJ Public Health2025; 3: e002149.

Murata F, Maeda M, Fukuda H*.

Claims-based analysis of zoster vaccine effectiveness against incident herpes zoster: The VENUS Study.

JMA Journal 2025; 8(4): 1399-1402.

Sato S, Kawazoe Y, Murata F, Maeda M, Fukuda H.

Estimation of the adjusted risk difference for very rare events, large samples, and extreme exposure frequency: Application of Vaccine Effectiveness, Networking, and Universal Safety study.

Annals of Clinical Epidemiology2025; 7(2): 50-60.

Kim S, Maeda M, Murata F, Fukuda H*.

Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: the VENUS study.

Vaccine 2024; 43(Pt 2): 126497.

Chikamochi T, Ishiguro C*, Mimura W, Maeda M, Murata F, Fukuda H.

Validation study of the claims-based algorithm using the International Classification of Diseases codes to identify patients with coronavirus disease in Japan from 2020 to 2022: The VENUS study.

Pharmacoepidemiology and Drug Safety 2024; in press.

Murata F, Maeda M, Fukuda H*.

Protective effects of 23-valent pneumococcal polysaccharide vaccination against mortality: The VENUS Study.

Open Forum Infectious Diseases 2024; 11(9): ofae530.

Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H.

Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS Study.

Human Vaccines & Immunotherapeutics 2024; 20(1): 2350091.

Maeda H, Toizumi M, Igarashi A, Maeda M, Oda F, Fukuda H.

Incidence of COVID-19 Hospitalization and Seizures by Vaccination in Youth in Japan: VENUS Study.

The 36th Annual Scientific Meeting of the Japan Epidemiological Association & The 3rd Joint Scientific Meeting with the IEA Western Pacific Region, Nagasaki January 28-30, 2026.

Zha L, Kimura Y, Komatsu M, Shimomura Y, Gon Y, Maeda M, Oda F, Komukai S, Kiyohara K, Kitamura T, Fukuda H.

Association of PPSV23 with Parkinson’s and Alzheimer’s Disease Risk: The VENUS Study.

The 36th Annual Scientific Meeting of the Japan Epidemiological Association & The 3rd Joint Scientific Meeting with the IEA Western Pacific Region, NagasakiJanuary 28-30, 2026.

Sung Y, Goto K, Maeda M, Oda F, Fukuda H.

Bias in vaccination coverage from incomplete in-migrant records in Japan: the VENUS Study.

The 36th Annual Scientific Meeting of the Japan Epidemiological Association & The 3rd Joint Scientific Meeting with the IEA Western Pacific Region, Nagasaki January 28-30, 2026.

Nishimura S, Kumamaru T, Maeda M, Oda F, Fukuda H.

Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Older Adults : the VENUS Study.

ISPE's 17th Asian Conference on Pharmacoepidemiology (ACPE 2025) 21-23 November 2025. Hong Kong, China.

三村亘, 石黒智恵子, 前田恵, 小田太史, 福田治久.

日本脳炎ワクチン接種率と限定出荷の影響の評価: VENUS Study.

第84回日本公衆衛生学会総会. 2025年10月29日～10月31日. 静岡.

福田治久.

自治体が実施する任意接種ワクチンの独自助成の実施状況.

第29回日本ワクチン学会/第66回日本臨床ウイルス学会合同学術集会. 2025年9月27日～28日.札幌.

Uemura Y, Shinozaki T, Shimizu Y, Mimura W, Fukuda H, Ishiguro C.

Safety Evaluation of Multiple Vaccination Regimens for the Elderly in Japan: The VENUS Study.

2025 ISPE Annual Meeting. Washington DC, USA.22-26 August 2025.

Morita H, Ishiguro C, Mimura W, Tsuzuki S, Terada-Hirashima J, Takeuchi Y, Maeda M, Fukuda H.

Assessment of the Safety of Human Papillomavirus Vaccination in Japan: VENUS Study.

2025 ISPE Annual Meeting. Washington DC, USA.22-26 August 2025.

Ishiguro C, Shinozaki T, Kumamaru H, Fukuda H, Mimura W, Shimizu Y, Uemura Y.

Developing the Framework of Epidemiological and Biostatistical Approaches for Post-Approval Vaccine Safety Assessment Using a Large Healthcare Database in Japan: Year 1 Progress.

2025 ISPE Annual Meeting. Washington DC, USA. 22-26 August 2025.

三村亘, 石黒智恵子, 清水陽介, 寺田純子, 前田恵, 村田典子, 福田治久

Target trial emulationによる高齢者インフルエンザワクチンの接種タイミングの評価: VENUS Study.

第35回日本疫学会学術総会2025年2月12日～14日. 高知

読売新聞．ワクチン事故防止へ体制整備

2023年11月13日

TBS. 報道の日2023 今こそ知っておきたいコロナワクチン見えてきた日本の課題

2023年12月30日

NHK. サイカルジャーナル. ワクチン効果と安全性実社会では？検証に挑む

2023年1月11日

朝日新聞．ワクチン副反応、海外にあり日本にない検証の仕組み　研究者らの試み

2022年12月16日